These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Different expression of the plasminogen activation system in renal thrombotic microangiopathy and the normal human kidney. Xu Y; Hagege J; Mougenot B; Sraer JD; Rønne E; Rondeau E Kidney Int; 1996 Dec; 50(6):2011-9. PubMed ID: 8943484 [TBL] [Abstract][Full Text] [Related]
4. Human renal microvascular endothelial cells as a potential target in the development of the hemolytic uremic syndrome as related to fibrinolysis factor expression, in vitro. Louise CB; Obrig TG Microvasc Res; 1994 May; 47(3):377-87. PubMed ID: 8084301 [TBL] [Abstract][Full Text] [Related]
5. Enhanced expression of plasminogen activator inhibitor 1 in patients with nephrotic syndrome. Yoshida Y; Shiiki H; Iwano M; Uyama H; Hamano K; Nishino T; Dohi K Nephron; 2001 May; 88(1):24-9. PubMed ID: 11340346 [TBL] [Abstract][Full Text] [Related]
6. Comprehensive genetic analysis of complement and coagulation genes in atypical hemolytic uremic syndrome. Bu F; Maga T; Meyer NC; Wang K; Thomas CP; Nester CM; Smith RJ J Am Soc Nephrol; 2014 Jan; 25(1):55-64. PubMed ID: 24029428 [TBL] [Abstract][Full Text] [Related]
8. Partial ADAMTS13 deficiency in atypical hemolytic uremic syndrome. Feng S; Eyler SJ; Zhang Y; Maga T; Nester CM; Kroll MH; Smith RJ; Afshar-Kharghan V Blood; 2013 Aug; 122(8):1487-93. PubMed ID: 23847193 [TBL] [Abstract][Full Text] [Related]
9. The role of von Willebrand factor in thrombotic microangiopathy. Noone DG; Riedl M; Licht C Pediatr Nephrol; 2018 Aug; 33(8):1297-1307. PubMed ID: 28748411 [TBL] [Abstract][Full Text] [Related]
10. Prognostic value of plasminogen activator inhibitor type 1 mRNA in microdissected glomeruli from transplanted kidneys. Delarue F; Hertig A; Alberti C; Vigneau C; Ammor M; Berrou J; Akposso K; Peraldi MN; Rondeau E; Sraer JD Transplantation; 2001 Oct; 72(7):1256-61. PubMed ID: 11602852 [TBL] [Abstract][Full Text] [Related]
11. [Atypical hemolytic-uremic syndrome related to abnormalities within the complement system]. Frémeaux-Bacchi V; Fakhouri F; Roumenina L; Dragon-Durey MA; Loirat C Rev Med Interne; 2011 Apr; 32(4):232-40. PubMed ID: 21376430 [TBL] [Abstract][Full Text] [Related]
12. Where are we with haemolytic uremic syndrome? Cavero T; Alonso M Med Clin (Barc); 2018 Oct; 151(8):329-335. PubMed ID: 29699703 [TBL] [Abstract][Full Text] [Related]
13. Expression of glomerular plasminogen activator inhibitor type 1 in glomerulonephritis. Hamano K; Iwano M; Akai Y; Sato H; Kubo A; Nishitani Y; Uyama H; Yoshida Y; Miyazaki M; Shiiki H; Kohno S; Dohi K Am J Kidney Dis; 2002 Apr; 39(4):695-705. PubMed ID: 11920334 [TBL] [Abstract][Full Text] [Related]
14. Complement activation in diseases presenting with thrombotic microangiopathy. Meri S Eur J Intern Med; 2013 Sep; 24(6):496-502. PubMed ID: 23743117 [TBL] [Abstract][Full Text] [Related]
15. How I treat: the clinical differentiation and initial treatment of adult patients with atypical hemolytic uremic syndrome. Cataland SR; Wu HM Blood; 2014 Apr; 123(16):2478-84. PubMed ID: 24599547 [TBL] [Abstract][Full Text] [Related]
16. Effect of sera from lupus patients on the glomerular endothelial fibrinolysis system. Sato R; Aizawa T; Imaizumi T; Tsugawa K; Kawaguchi S; Seya K; Terui K; Tanaka H Pediatr Int; 2022 Jan; 64(1):e15099. PubMed ID: 35522716 [TBL] [Abstract][Full Text] [Related]
17. Pathogenesis of Atypical Hemolytic Uremic Syndrome. Yoshida Y; Kato H; Ikeda Y; Nangaku M J Atheroscler Thromb; 2019 Feb; 26(2):99-110. PubMed ID: 30393246 [TBL] [Abstract][Full Text] [Related]
18. Thrombotic microangiopathy: focus on atypical hemolytic uremic syndrome. Sperati CJ; Moliterno AR Hematol Oncol Clin North Am; 2015 Jun; 29(3):541-59. PubMed ID: 26043391 [TBL] [Abstract][Full Text] [Related]
19. Biphasic regulation of plasminogen activator/inhibitor by LDL in mesangial cells. Song CY; Kim BC; Hong HK; Kim BK; Kim YS; Lee HS Am J Physiol Renal Physiol; 2002 Sep; 283(3):F423-30. PubMed ID: 12167592 [TBL] [Abstract][Full Text] [Related]
20. Heme Drives Susceptibility of Glomerular Endothelium to Complement Overactivation Due to Inefficient Upregulation of Heme Oxygenase-1. May O; Merle NS; Grunenwald A; Gnemmi V; Leon J; Payet C; Robe-Rybkine T; Paule R; Delguste F; Satchell SC; Mathieson PW; Hazzan M; Boulanger E; Dimitrov JD; Fremeaux-Bacchi V; Frimat M; Roumenina LT Front Immunol; 2018; 9():3008. PubMed ID: 30619356 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]